TIDMODX
Omega Diagnostics Group PLC
24 February 2021
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
UK-RTC statement on AbC-19(TM) rapid antibody test
Lateral flow test data shows potential for companion diagnostic
to the Pfizer-BioNTech COVID-19 vaccine
AbC-19(TM) rapid antibody test was effective in demonstrating
immune response following first dose vaccination
Omega (AIM: ODX), the medical diagnostics company focused on
CD4, infectious diseases and food intolerance, notes the press
release issued today by the UK Rapid Test Consortium ("UK-RTC"), of
which Omega is a partner, which presents new data relating to the
performance of the AbC-19(TM) rapid antibody test when used as a
companion diagnostic to the Pfizer-BioNTech COVID-19 vaccine. The
initial study performed at the University of Birmingham highlighted
the effectiveness of the AbC-19(TM) rapid antibody test in
demonstrating immune response following vaccination.
During the study t he AbC-19(TM) Rapid Test was used to test
individuals who had been given a single dose of the Pfizer-BioNTech
COVID-19 vaccine. In total 193 individuals who had received a
COVID-19 vaccine were tested for the presence of IgG antibodies to
the full trimeric spike using the AbC-19(TM) test. Of these
individuals, a sub-set of 65 patients had been determined to have
previously been infected with COVID-19, and 128 had no previous
infection. The study also concluded that patients previously
infected with COVID-19 showed a stronger immune response to the
first dose of the Pfizer-BioNTech COVID-19 vaccine.
Following the study the statement from the UK-RTC said:
"The initial data from the study being performed at the
University of Birmingham supports the rationale that vaccination
programmes could benefit from determining an individual's antibody
status not only after vaccination but also prior to vaccination.
Should these results continue to be seen in further studies, and
with other vaccines, this demonstrates that the AbC-19 (TM)
antibody test could potentially assist in patient stratification
and resource management in overburdened international healthcare
settings."
The UK-RTC press release is reproduced in full at the end of the
statement and can be found here:
https://www.abc19.com/
Contacts:
Omega Diagnostics Group PLC www.omegadiagnostics.com
Colin King, Chief Executive via Walbrook PR
Kieron Harbinson, Group Finance
Director
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Edward Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
Press release from the UK-RTC (issued on 24 February 2021)
The UK-RTC, a consortium of UK diagnostic companies including
Abingdon Health, CIGA Healthcare, BBI Solutions and Omega
Diagnostics, presents new data examining the performance of the
AbC-19(TM) rapid antibody test when used with 193 individuals that
had received a single dose of the Pfizer-BioNTech COVID-19
vaccination. This study was performed at the University of
Birmingham.
The sample population included a sub-set of 65 patients that had
previously been infected with COVID-19, and 128 that had no
previous infection. The highlights of the data/study are as
follows:
-- The AbC-19(TM) rapid antibody test was effective in
demonstrating the immune response of patients to the first dose of
the Pfizer-BioNTech COVID-19 vaccine,
-- The study highlighted a differential immune response of two
cohorts of patients: those previously infected with COVID-19 and
those not infected;
-- Patients previously infected with COVID-19 showed a stronger
immune response to the first dose of the Pfizer-BioNTech COVID-19
vaccine;
The initial data from the study being performed at the
University of Birmingham supports the rationale that vaccination
programmes could benefit from determining an individual's antibody
status not only after vaccination but also prior to vaccination
Should these results continue to be seen in further studies, and
with other vaccines, this demonstrates that the AbC-19 (TM)
antibody test could potentially assist in patient stratification
and resource management in overburdened international healthcare
settings.
The AbC-19(TM) Rapid Test was used to test samples from
individuals who had been given a single dose of the Pfizer-BioNTech
COVID-19 vaccine. In total 193 individuals who had received a
COVID-19 vaccine were tested for the presence of IgG antibodies to
the full trimeric spike using the AbC-19(TM) test.
Of the patients involved in the study, the AbC-19(TM) rapid test
identified 181 (94%) as testing positive for the presence of IgG
antibodies to COVID-19, with some samples from those with previous
infection demonstrating a positive result as little as 1-4 days
post vaccination. Using a cut-off of 13 days post-vaccination
(which is the minimum recommendation for determining antibody
status using the AbC-19(TM) rapid test) 137 out of 140 of samples,
or 98% of patients, were identified as testing positive for the
presence of IgG antibodies.
Using the WHO classification of the lateral flow device test
line, results were classified as:
-- 0 (negative)
-- 1 (very weak but definitely reactive)
-- 2 (medium to strong reactivity)
Of the 193 individuals examined, 128 (66%) patients were
determined as not having a previous COVID-19 infection and thus
naïve samples, with 65 (34%) patients identified as having a
previous COVID-19 infection.
When applying the above scoring to the samples taken 13 days
after the single vaccination, 43.3% of the naïve samples scored
medium to strong test line response with 53.8% showing a weaker
response and 2.9% having a negative result. In contrast, those who
had previously been infected with COVID-19 had a stronger response
in 75% individuals, while 25% showed a weaker response with no
negative results. It would be expected for the IgG anti-spike
antibody levels to continue to rise with time and following a
second vaccination.
Further studies are being performed to expand this data set and
are expected to be available in the next few weeks.
About the UK-RTC
The UK Rapid Test Consortium (UK-RTC) was founded in response to
a UK Government call for businesses to work together on a rapid
antibody test to be rolled out nationally. Led by Abingdon Health,
it's members also include, BBI Solutions, CIGA Healthcare and Omega
Diagnostics. The Abc-19(TM) is approved in Europe and the UK for
professional use and is available for sale.
About the AbC-19(TM) Rapid Test
The AbC-19(TM) Rapid Test is a single use test for the detection
of neutralising IgG antibodies to the full trimeric spike protein
of the SARS-CoV-2 virus in human capillary whole blood.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAPPUMWPUPGPGW
(END) Dow Jones Newswires
February 24, 2021 02:00 ET (07:00 GMT)
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Apr 2024 to May 2024
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From May 2023 to May 2024